4.3 Article

Stavudine Concentrations in Women Receiving Postpartum Antiretroviral Treatment and Their Breastfeeding Infants

Journal

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAI.0b013e31825ddcfa

Keywords

stavudine concentrations; breast milk; mother-to-child transmission; HIV

Funding

  1. National Institute of Allergy and Infectious Diseases (NIAID/NIH) [R01-AI087139]
  2. International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) Network [UM1-AI068632]
  3. HIV Prevention Trials Network (HPTN)
  4. NIAID
  5. National Institute on Drug Abuse
  6. National Institute of Mental Health
  7. Office of AIDS Research, of the NIH, Department of Health and Human Services [UM1-AI068613]

Ask authors/readers for more resources

First-line antiretroviral treatment regimens in resource-limited settings used in breastfeeding mothers often include stavudine (d4T). Limited data describing d4T concentrations in breast milk are available. We analyzed d4T concentrations in 52 mother-infant pairs using ultra-performance liquid chromatography-tandem mass spectrometry (lower limit of quantification: 5 ng/mL in plasma, 20 ng/mL in breast milk). Median (interquartile range) d4T concentrations were 86 (36-191) ng/mL in maternal plasma, 151 (48-259) ng/mL in whole milk, 190 (58-296) ng/mL in skim milk, and <5 (<5 to <5) ng/mL in infant plasma. Although d4T is concentrated in breast milk relative to maternal plasma, the infant d4T dose received from breast milk is very small and not clinically significant.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available